Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15044037 | 1.00 | TSHR (0.43) | TSHRUSP2CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL12653403 | 0.97 | USP2 (0.42) | TSHRUSP2CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL3096192 | 0.88 | TSHR (0.38) | TSHRUSP2CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL16153750 | 0.88 | TSHR (0.38) | TSHRUSP2CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL3096199 | 0.88 | TSHR (0.38) | TSHRUSP2CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL28576046 | 0.88 | TSHR (0.38) | TSHRUSP2CYP3A4SMN1; SMN2LMNA | |
| SCHEMBL2381476 | 0.85 | — | — | |
| SCHEMBL29157267 | 0.85 | THRB (0.56) | TSHRUSP2CYP3A4LMNAALDH1A1 | |
| SCHEMBL2382234 | 0.85 | — | — | |
| SCHEMBL62155 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160168183-A1 | Conjugates Containing Hydrophilic Spacer Linkers | ENDOCYTE INC (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | SLC7A11, CXCR2, TPX2 | TSHR 2466/4885USP2 583/4885CYP3A4 3409/4885 |
| US-20160168183-A1 | Conjugates Containing Hydrophilic Spacer Linkers | CD44, HAVCR2, HCAR1 | TSHR 566/4885USP2 2081/4885CYP3A4 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.